## Abstract The aim of the present study was to compare the decline of HBV DNA during peginterferon (PEG‐IFN) therapy with spontaneous HBV DNA decline in placebo‐treated patients with hepatitis B e antigen (HBeAg)‐positive chronic hepatitis B. A total of 136 patients who participated in a randomize
Low HBV-DNA levels in end-stage renal disease patients with HBeAg-negative chronic hepatitis B
✍ Scribed by Renata S. Moutinho; Renata M. Perez; José O. Medina-Pestana; Mauro S. Figueiredo; Sandra Koide; Fernando Lopes Alberto; Antonio Eduardo B. Silva; Maria Lucia G. Ferraz
- Publisher
- John Wiley and Sons
- Year
- 2006
- Tongue
- English
- Weight
- 107 KB
- Volume
- 78
- Category
- Article
- ISSN
- 0146-6615
No coin nor oath required. For personal study only.
✦ Synopsis
Abstract
In end‐stage renal disease patients treated by hemodialysis with HBeAg‐negative chronic hepatitis B virus (HBV) infection, the evaluation of the presence of viral replication is essential in the assessment for renal transplantation. Data on HBV viral load, prevalence of precore mutations, as well as the influence of HCV coinfection on HBV‐DNA levels in this group of patients is scarce. The aim of this study was to determine the HBV viral load in HBsAg‐positive/HBeAg‐negative hemodialysis patients; to compare HBV‐DNA levels between isolated HBV infection carriers and HBV‐HCV coinfected patients, and to evaluate the prevalence of precore mutations in these patients. Fifty hemodialysis patients with chronic HBeAg‐negative HBV infection were studied. Viral load was determined by PCR (Amplicor HBV Monitor‐Roche). The detection of precore mutations was made by sequencing. Of a total of 50 patients, 76% were male, with a mean age of 44 ± 11 years. Anti‐HCV was positive in 56% of patients. HBV‐DNA was undetectable in 58% of patients; 24% had HBV‐DNA <10,000 copies/ml, 12% between 10,000–100,000 copies/ml, and only 6% had HBV‐DNA >100,000 copies/ml. There was no difference in the viral load of patients infected only by HBV and HBV‐HCV co‐infected patients (P = 0.96). Precore mutations were detected in only 8% of cases. In conclusion, hemodialysis patients with HBeAg‐negative HBV infection had a low viral load. Precore mutations were infrequent and the presence of anti‐HCV has not influenced the levels of HBV‐DNA. J. Med. Virol. 78:1284–1288, 2006. © 2006 Wiley‐Liss, Inc.
📜 SIMILAR VOLUMES
Low-level viremia due to hepatitis B virus (HBV) was demonstrated in the sera of two patients diagnosed previously as having non-B, non-C chronic hepatitis. Both patients had a "silent" HBV infection, because they were negative for both hepatitis B surface antigen (HBsAg) and anti-hepatitis B core a
## Abstract Peginterferon (PEG‐IFN) results in HBeAg loss combined with virologic response in only a minority of patients with HBeAg positive chronic hepatitis B. Baseline predictors of response to PEG‐IFN include HBV‐genotype, pre‐treatment HBV DNA levels, and ALT. The aims of this study were to d